Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Sunscreen Guidance: Absorption Data Is A MUsT For GRASE Review

Executive Summary

The agency maintains maximal usage trials are essential in sunscreen ingredient GRASE assessments, despite industry objections that the tests have not been used for UV filters and no protocol is established. FDA’s final guidance closely mirrors its draft issued a year ago, which stakeholders projected would further delay consumer access to updated sunscreen products.

Advertisement

Related Content

OTC Monograph Application Reviews Get Deadlines, Not GRASE Flexibility
Sunscreen Industry Asks FDA For Flexibility Despite Guidances' Rigidity
Sunscreen Group Remains Cloudy About FDA's Ingredient Evaluations
Manufacturers Argue FDA Sunscreen Reviews Keep Outside Science In Shade
Sunscreen Guidances Underscore FDA Standards Aren’t Changing
‘Vast Majority’ Of Antibac Soaps Need Reformulation Under FDA Final Rule
Sunscreen Data Guidance Risk/Benefit Balance Uneven – Comments

Topics

Advertisement
UsernamePublicRestriction

Register

PS119579

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel